CR20190162A - Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado - Google Patents
Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activadoInfo
- Publication number
- CR20190162A CR20190162A CR20190162A CR20190162A CR20190162A CR 20190162 A CR20190162 A CR 20190162A CR 20190162 A CR20190162 A CR 20190162A CR 20190162 A CR20190162 A CR 20190162A CR 20190162 A CR20190162 A CR 20190162A
- Authority
- CR
- Costa Rica
- Prior art keywords
- una
- coagulation factor
- hemorragia
- factor
- bleeding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383933P | 2016-09-06 | 2016-09-06 | |
US201662437281P | 2016-12-21 | 2016-12-21 | |
US201762485514P | 2017-04-14 | 2017-04-14 | |
PCT/JP2017/031933 WO2018047813A1 (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190162A true CR20190162A (es) | 2019-05-13 |
Family
ID=61561893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190162A CR20190162A (es) | 2016-09-06 | 2017-09-05 | Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado |
Country Status (15)
Country | Link |
---|---|
US (4) | US11352438B2 (es) |
EP (1) | EP3509637A4 (es) |
JP (2) | JP7125932B2 (es) |
KR (2) | KR102560808B1 (es) |
CN (1) | CN109661241A (es) |
AU (1) | AU2017325240A1 (es) |
BR (1) | BR112019003989A2 (es) |
CA (1) | CA3035327A1 (es) |
CR (1) | CR20190162A (es) |
MA (1) | MA46200A (es) |
MX (1) | MX2019002510A (es) |
RU (1) | RU2766233C2 (es) |
SG (1) | SG11201901961SA (es) |
TW (1) | TWI786061B (es) |
WO (1) | WO2018047813A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
PH12016502073A1 (en) | 2010-11-17 | 2018-01-29 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
KR102560808B1 (ko) | 2016-09-06 | 2023-07-27 | 추가이 세이야쿠 가부시키가이샤 | 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법 |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
MA50893A (fr) | 2017-11-15 | 2020-09-23 | Novo Nordisk As | Liants de facteur x renforçant l'activation fx |
FR3082427B1 (fr) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x |
PL3723858T3 (pl) | 2018-12-21 | 2022-03-07 | Kymab Limited | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
US20220305122A1 (en) * | 2019-10-11 | 2022-09-29 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition |
TW202207984A (zh) * | 2019-10-11 | 2022-03-01 | 日商中外製藥股份有限公司 | 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品 |
USD967377S1 (en) | 2020-10-08 | 2022-10-18 | Samsung Electronics Co., Ltd. | Air purifier |
KR20230130558A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
KR20230130561A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
KR20230130560A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
IL89491A0 (en) | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
KR100236375B1 (ko) | 1989-12-11 | 1999-12-15 | 오트리브 데이비스 더블유 | 진단제 또는 치료제를 목표부위에 타게팅하기 위한 제제 및 키트 |
TW212184B (es) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
JPH05184383A (ja) | 1990-06-19 | 1993-07-27 | Dainabotsuto Kk | 二重特異性抗体 |
JPH05199894A (ja) | 1990-08-20 | 1993-08-10 | Takeda Chem Ind Ltd | 二重特異性抗体および抗体含有薬剤 |
JPH05304992A (ja) | 1991-06-20 | 1993-11-19 | Takeda Chem Ind Ltd | ハイブリッド・モノクローナル抗体および抗体含有薬剤 |
JPH06104071A (ja) | 1991-08-30 | 1994-04-15 | Jasco Corp | 発熱体セラミックス溶接加工方法 |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
JPH05203652A (ja) | 1992-01-28 | 1993-08-10 | Fuji Photo Film Co Ltd | 抗体酵素免疫分析法 |
JPH05213775A (ja) | 1992-02-05 | 1993-08-24 | Otsuka Pharmaceut Co Ltd | Bfa抗体 |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
AU7214294A (en) | 1993-07-01 | 1995-01-24 | Dade International Inc. | Process for the preparation of factor x depleted plasma |
WO1996001653A1 (en) | 1994-07-11 | 1996-01-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
CA2207869A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
JP3032287U (ja) | 1996-06-10 | 1996-12-17 | 幸喜 高橋 | 人 形 |
JPH10165184A (ja) | 1996-12-16 | 1998-06-23 | Tosoh Corp | 抗体、遺伝子及びキメラ抗体の製法 |
JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
AU2001264946A1 (en) | 2000-05-24 | 2001-12-03 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
JP4908721B2 (ja) | 2000-07-17 | 2012-04-04 | 中外製薬株式会社 | 生理活性を有するリガンドのスクリーニング方法 |
EP2116265B1 (en) | 2000-10-12 | 2020-12-23 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
EP1327681A4 (en) | 2000-10-20 | 2004-09-01 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibodies |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
ATE512989T1 (de) | 2002-04-15 | 2011-07-15 | Chugai Pharmaceutical Co Ltd | Verfahren zur herstellung von scdb-bibliotheken |
US7732149B2 (en) | 2002-04-26 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening agonistic antibodies |
EP2314629B2 (en) | 2002-07-18 | 2022-11-16 | Merus N.V. | Recombinant production of mixtures of antibodies |
AU2003303543A1 (en) | 2002-12-26 | 2004-07-29 | Chugai Seiyaku Kabushiki Kaisha | Agonist antibody against heteroreceptor |
EP1605058B1 (en) | 2003-01-21 | 2009-05-13 | Chugai Seiyaku Kabushiki Kaisha | Method of screening light chain of antibody light chains |
CA2517310C (en) | 2003-02-28 | 2015-11-24 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations comprising a poloxamer |
GB2400851B (en) | 2003-04-25 | 2004-12-15 | Bioinvent Int Ab | Identifying binding of a polypeptide to a polypeptide target |
WO2004111233A1 (ja) | 2003-06-11 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
EP1693448A4 (en) | 2003-10-14 | 2008-03-05 | Chugai Pharmaceutical Co Ltd | DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
JP4460414B2 (ja) | 2004-10-06 | 2010-05-12 | 日本電信電話株式会社 | 血圧計 |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
SI1876236T1 (sl) | 2005-04-08 | 2014-11-28 | Chugai Seiyaku Kabushiki Kaisha | Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi |
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
KR101856792B1 (ko) | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
BR112012031920A2 (pt) | 2010-06-14 | 2017-05-16 | Paion Deutschland Gmbh | tratamento de coagulopatias com hiperfibrinólise. |
PH12016502073A1 (en) | 2010-11-17 | 2018-01-29 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
SI2822587T1 (sl) | 2012-03-08 | 2016-04-29 | F. Hoffmann-La Roche Ag | Farmacevtska oblika abeta protitelesa |
EP3065768B1 (en) * | 2013-11-04 | 2020-09-23 | The Regents of the University of California | Composition for use in treatment or prevention of conditions associated with bleeding or hypocoagulationcompostion |
TW201625299A (zh) * | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
EP3280444B1 (en) | 2015-04-10 | 2024-05-08 | Adimab, LLC | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
JP6698102B2 (ja) | 2015-04-17 | 2020-05-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 凝固因子と多重特異的抗体を用いた併用療法 |
JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物 |
TWI797073B (zh) | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | 包含雙特異性抗體建構物之醫藥組合物 |
CA3016301A1 (en) | 2016-04-28 | 2017-11-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
KR102560808B1 (ko) | 2016-09-06 | 2023-07-27 | 추가이 세이야쿠 가부시키가이샤 | 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법 |
WO2018181870A1 (ja) | 2017-03-31 | 2018-10-04 | 公立大学法人奈良県立医科大学 | 血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物 |
BR112020008393A2 (pt) | 2017-11-01 | 2020-11-03 | Chugai Seiyaku Kabushiki Kaisha | variante e isoforma de anticorpos com atividade biológica reduzida |
TW202207984A (zh) | 2019-10-11 | 2022-03-01 | 日商中外製藥股份有限公司 | 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品 |
-
2017
- 2017-09-05 KR KR1020197009689A patent/KR102560808B1/ko active IP Right Grant
- 2017-09-05 MX MX2019002510A patent/MX2019002510A/es unknown
- 2017-09-05 SG SG11201901961SA patent/SG11201901961SA/en unknown
- 2017-09-05 AU AU2017325240A patent/AU2017325240A1/en active Pending
- 2017-09-05 BR BR112019003989A patent/BR112019003989A2/pt unknown
- 2017-09-05 EP EP17848753.4A patent/EP3509637A4/en active Pending
- 2017-09-05 US US16/330,269 patent/US11352438B2/en active Active
- 2017-09-05 RU RU2019109464A patent/RU2766233C2/ru active
- 2017-09-05 WO PCT/JP2017/031933 patent/WO2018047813A1/en unknown
- 2017-09-05 JP JP2019511669A patent/JP7125932B2/ja active Active
- 2017-09-05 CR CR20190162A patent/CR20190162A/es unknown
- 2017-09-05 KR KR1020237025275A patent/KR20230117462A/ko not_active Application Discontinuation
- 2017-09-05 MA MA046200A patent/MA46200A/fr unknown
- 2017-09-05 CN CN201780054106.1A patent/CN109661241A/zh active Pending
- 2017-09-05 CA CA3035327A patent/CA3035327A1/en active Pending
- 2017-09-05 TW TW106130277A patent/TWI786061B/zh active
-
2022
- 2022-05-31 US US17/828,752 patent/US20220315667A1/en not_active Abandoned
- 2022-08-15 JP JP2022129184A patent/JP2022166174A/ja active Pending
-
2023
- 2023-01-19 US US18/156,559 patent/US20230159658A1/en not_active Abandoned
- 2023-09-14 US US18/466,900 patent/US20240052058A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2019002510A (es) | 2019-06-24 |
WO2018047813A1 (en) | 2018-03-15 |
US11352438B2 (en) | 2022-06-07 |
RU2019109464A (ru) | 2020-10-08 |
US20230159658A1 (en) | 2023-05-25 |
SG11201901961SA (en) | 2019-04-29 |
JP2019530654A (ja) | 2019-10-24 |
CA3035327A1 (en) | 2018-03-15 |
MA46200A (fr) | 2019-07-17 |
US20220315667A1 (en) | 2022-10-06 |
KR102560808B1 (ko) | 2023-07-27 |
US20240052058A1 (en) | 2024-02-15 |
CN109661241A (zh) | 2019-04-19 |
RU2766233C2 (ru) | 2022-02-10 |
US20190194352A1 (en) | 2019-06-27 |
JP2022166174A (ja) | 2022-11-01 |
KR20190044673A (ko) | 2019-04-30 |
JP7125932B2 (ja) | 2022-08-25 |
EP3509637A1 (en) | 2019-07-17 |
KR20230117462A (ko) | 2023-08-08 |
RU2019109464A3 (es) | 2020-12-21 |
AU2017325240A1 (en) | 2019-05-02 |
EP3509637A4 (en) | 2020-05-27 |
TWI786061B (zh) | 2022-12-11 |
BR112019003989A2 (pt) | 2019-05-28 |
TW201822815A (zh) | 2018-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190162A (es) | Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado | |
CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
CO2017001317A2 (es) | Composición farmacéutica con anticuerpos anti cd40 y kit | |
CL2019000266A1 (es) | Composición de cannabis. | |
ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
ECSP17073878A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
PE20180671A1 (es) | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematologicas positivas para cd38 | |
BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
CR20190403A (es) | Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma | |
CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
BR112016026560A2 (pt) | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção | |
BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
BR112018068027A2 (pt) | método para tratar câncer em um paciente e composição farmacêutica |